Chronic Kidney Disease Market: 5 Emerging Therapies to Watch as the Treatment Landscape Expected to Evolve by 2036 | DelveInsight
Why now
Thesis: Long-dated pipeline story, no near-term trade
Catalyst to watch: Trial readouts or approvals for named therapies
Main risk: No named public company to act on
Why it matters
Pipeline competition in kidney disease could shift future market share among drugmakers, but no listed tickers are named.
Details
A diversified late-stage pipeline encompassing endothelin receptor antagonists, aldosterone synthase inhibitors such as lorundrostat, APOL1 inhibitors including MZE829, and cell therapy approaches such as rilparencel is poised to intensify competition, with each modality addressing...
Related assets & topics
HealthcareSources
- prnewswire · 2026-09-24 14:31 UTC